KR100451312B1 - 그룹 오 에이취아이브이-1 바이러스에 기인하는 감염의 검출을 위한 생물학적 시험에 사용가능한 합성 펩티드 - Google Patents
그룹 오 에이취아이브이-1 바이러스에 기인하는 감염의 검출을 위한 생물학적 시험에 사용가능한 합성 펩티드 Download PDFInfo
- Publication number
- KR100451312B1 KR100451312B1 KR10-1999-7009296A KR19997009296A KR100451312B1 KR 100451312 B1 KR100451312 B1 KR 100451312B1 KR 19997009296 A KR19997009296 A KR 19997009296A KR 100451312 B1 KR100451312 B1 KR 100451312B1
- Authority
- KR
- South Korea
- Prior art keywords
- peptide
- group
- hiv
- seq
- formula
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 218
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 70
- 208000015181 infectious disease Diseases 0.000 title abstract description 6
- 241000700605 Viruses Species 0.000 title description 5
- 238000004166 bioassay Methods 0.000 title 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 208000031886 HIV Infections Diseases 0.000 claims description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- CWOSXNKDOACNJN-BZSNNMDCSA-N Val-Arg-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N CWOSXNKDOACNJN-BZSNNMDCSA-N 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 238000003018 immunoassay Methods 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 150000003573 thiols Chemical class 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 2
- 150000003254 radicals Chemical class 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 17
- 238000001514 detection method Methods 0.000 abstract description 6
- 150000001413 amino acids Chemical class 0.000 description 53
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 51
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 51
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 50
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 50
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 50
- 235000001014 amino acid Nutrition 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 26
- 239000011347 resin Substances 0.000 description 16
- 229920005989 resin Polymers 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 241001430294 unidentified retrovirus Species 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- WQOHKVRQDLNDIL-YJRXYDGGSA-N Tyr-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O WQOHKVRQDLNDIL-YJRXYDGGSA-N 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 108010069495 cysteinyltyrosine Proteins 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- TUIOUEWKFFVNLH-DCAQKATOSA-N Leu-Val-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(O)=O TUIOUEWKFFVNLH-DCAQKATOSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 9
- OXVPMZVGCAPFIG-BQFCYCMXSA-N Val-Gln-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N OXVPMZVGCAPFIG-BQFCYCMXSA-N 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- GFFRWIJAFFMQGM-NUMRIWBASA-N Asn-Glu-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GFFRWIJAFFMQGM-NUMRIWBASA-N 0.000 description 8
- CEZSLNCYQUFOSL-BQBZGAKWSA-N Cys-Arg-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O CEZSLNCYQUFOSL-BQBZGAKWSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 7
- BCAVNDNYOGTQMQ-AAEUAGOBSA-N Ser-Trp-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(O)=O BCAVNDNYOGTQMQ-AAEUAGOBSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- CIVXDCMSSFGWAL-YUMQZZPRSA-N Cys-Lys-Gly Chemical compound C(CCN)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CS)N CIVXDCMSSFGWAL-YUMQZZPRSA-N 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 5
- ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical compound [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 5
- CCDFBRZVTDDJNM-GUBZILKMSA-N Ala-Leu-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O CCDFBRZVTDDJNM-GUBZILKMSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 4
- 239000007979 citrate buffer Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000007363 ring formation reaction Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 3
- TWHDOEYLXXQYOZ-FXQIFTODSA-N Gln-Asn-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N TWHDOEYLXXQYOZ-FXQIFTODSA-N 0.000 description 3
- XFAUJGNLHIGXET-AVGNSLFASA-N Gln-Leu-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O XFAUJGNLHIGXET-AVGNSLFASA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000880493 Leptailurus serval Species 0.000 description 3
- IAJFFZORSWOZPQ-SRVKXCTJSA-N Leu-Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IAJFFZORSWOZPQ-SRVKXCTJSA-N 0.000 description 3
- HOMFINRJHIIZNJ-HOCLYGCPSA-N Leu-Trp-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(O)=O HOMFINRJHIIZNJ-HOCLYGCPSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 229920000361 Poly(styrene)-block-poly(ethylene glycol) Polymers 0.000 description 3
- CJDZKZFMAXGUOJ-IHRRRGAJSA-N Val-Cys-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N CJDZKZFMAXGUOJ-IHRRRGAJSA-N 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 3
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 108010038745 tryptophylglycine Proteins 0.000 description 3
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 description 2
- 240000003291 Armoracia rusticana Species 0.000 description 2
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- VXDXZGYXHIADHF-YJRXYDGGSA-N Cys-Tyr-Thr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VXDXZGYXHIADHF-YJRXYDGGSA-N 0.000 description 2
- OVSKVOOUFAKODB-UWVGGRQHSA-N Gly-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OVSKVOOUFAKODB-UWVGGRQHSA-N 0.000 description 2
- LGQZOQRDEUIZJY-YUMQZZPRSA-N Gly-Cys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](CS)NC(=O)CN)C(O)=O LGQZOQRDEUIZJY-YUMQZZPRSA-N 0.000 description 2
- IRNSXVOWSXSULE-DCAQKATOSA-N Lys-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN IRNSXVOWSXSULE-DCAQKATOSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 2
- -1 acetamidomethyl Chemical group 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 108010064235 lysylglycine Proteins 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N ornithyl group Chemical group N[C@@H](CCCN)C(=O)O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- BOKLLPVAQDSLHC-FXQIFTODSA-N Ala-Val-Cys Chemical compound C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)O)N BOKLLPVAQDSLHC-FXQIFTODSA-N 0.000 description 1
- UHFUZWSZQKMDSX-DCAQKATOSA-N Arg-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UHFUZWSZQKMDSX-DCAQKATOSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- PQAIOUVVZCOLJK-FXQIFTODSA-N Asn-Gln-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N PQAIOUVVZCOLJK-FXQIFTODSA-N 0.000 description 1
- GOKCTAJWRPSCHP-VHWLVUOQSA-N Asn-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)N)N GOKCTAJWRPSCHP-VHWLVUOQSA-N 0.000 description 1
- XHTUGJCAEYOZOR-UBHSHLNASA-N Asn-Ser-Trp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O XHTUGJCAEYOZOR-UBHSHLNASA-N 0.000 description 1
- WNGZKSVJFDZICU-XIRDDKMYSA-N Asp-Leu-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)N WNGZKSVJFDZICU-XIRDDKMYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- PRBLYKYHAJEABA-SRVKXCTJSA-N Gln-Arg-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O PRBLYKYHAJEABA-SRVKXCTJSA-N 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical group CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- RFUBXQQFJFGJFV-GUBZILKMSA-N Leu-Asn-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O RFUBXQQFJFGJFV-GUBZILKMSA-N 0.000 description 1
- OGCQGUIWMSBHRZ-CIUDSAMLSA-N Leu-Asn-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OGCQGUIWMSBHRZ-CIUDSAMLSA-N 0.000 description 1
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 1
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 1
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- IXEGQBJZDIRRIV-QEJZJMRPSA-N Trp-Asn-Glu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O IXEGQBJZDIRRIV-QEJZJMRPSA-N 0.000 description 1
- MHCLIYHJRXZBGJ-AAEUAGOBSA-N Trp-Gly-Cys Chemical compound N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)NCC(=O)N[C@@H](CS)C(=O)O MHCLIYHJRXZBGJ-AAEUAGOBSA-N 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
아미노산 잔기 | NH2보호 | 측쇄보호 | 커플링 방법 | EQ수-커플링기간 |
Glu | Fmoc | OtBu | DIPCDI/HOBt | 5eq-30분 |
Asn | Fmoc | Trt | DIPCDI/HOBt | 5eq-30분 |
Trp | Fmoc | Boc | DIPCDI/HOBt | 5eq-30분 |
Gln | Fmoc | Trt | DIPCDI/HOBt | 5eq-30분 |
Val | Fmoc | DIPCDI/HOBt | 5eq-30분 | |
Ser | Fmoc | tBu | DIPCDI/HOBt | 5eq-30분 |
Thr | Fmoc | tBu | DIPCDI/HOBt | 5eq-30분 |
Tyr | Fmoc | tBu | DIPCDI/HOBt | 5eq-30분 |
Cys | Fmoc | Trt | DIPCDI/HOBt | 5eq-30분 |
Val | Fmoc | DIPCDI/HOBt | 5eq-30분 | |
Leu | Fmoc | DIPCDI/HOBt | 5eq-30분 | |
Arg | Fmoc | Pbf | DIPCDI/HOBt | 5eq-30분 |
Gly | Fmoc | DIPCDI/HOBt | 5eq-30분 | |
Arg | Fmoc | Pbf | DIPCDI/HOBt | 5eq-30분 |
Cys | Fmoc | Trt | DIPCDI/HOBt | 5eq-30분 |
Gly | Fmoc | DIPCDI/HOBt | 5eq-30분 | |
Trp | Fmoc | Boc | DIPCDI/HOBt | 5eq-30분 |
Leu | Fmoc | DIPCDI/HOBt | 5eq-30분 | |
Ser | Fmoc | tBu | DIPCDI/HOBt | 5eq-30분 |
Leu | Fmoc | DIPCDI/HOBt | 5eq-30분 | |
Leu | Fmoc | DIPCDI/HOBt | 5eq-30분 |
아미노산잔기 | NH2보호 | 측쇄보호 | 커플링 방법 | EQ수-커플링기간 |
Val | Fmoc | DIPCDI/HOBt | 5eq-45분 | |
Ser | Fmoc | tBu | DIPCDI/HOBt | 5eq-45분 |
Thr | Fmoc | tBu | DIPCDI/HOBt | 5eq-45분 |
Tyr | Fmoc | tBu | DIPCDI/HOBt | 5eq-45분 |
Cys | Fmoc | Trt | DIPCDI/HOBt | 5eq-45분 |
Val | Fmoc | DIPCDI/HOBt | 5eq-45분 | |
Leu | Fmoc | DIPCDI/HOBt | 5eq-45분 | |
Arg | Fmoc | Pbf | DIPCDI/HOBt | 5eq-45분 |
Gly | Fmoc | DIPCDI/HOBt | 5eq-45분 | |
Lys | Fmoc | Boc | DIPCDI/HOBt | 5eq-45분 |
Cys | Fmoc | Trt | DIPCDI/HOBt | 5eq-45분 |
Gly | Fmoc | DIPCDI/HOBt | 5eq-45분 | |
Trp | Fmoc | Boc | DIPCDI/HOBt | 5eq-45분 |
Ser | Fmoc | tBu | DIPCDI/HOBt | 5eq-45분 |
Asn | Fmoc | Trt | DIPCDI/HOBt | 5eq-45분 |
Leu | Fmoc | DIPCDI/HOBt | 5eq-45분 | |
Leu | Fmoc | DIPCDI/HOBt | 5eq-45분 | |
Arg | Fmoc | Pbf | DIPCDI/HOBt | 5eq-45분 |
Gln | Fmoc | Trt | DIPCDI/HOBt | 5eq-45분 |
Gln | Fmoc | Trt | DIPCDI/HOBt | 5eq-45분 |
Asn | Fmoc | Trt | DIPCDI/HOBt | 5eq-45분 |
Leu | Fmoc | DIPCDI/HOBt | 5eq-45분 | |
Leu | Fmoc | DIPCDI/HOBt | 5eq-45분 | |
Thr | Fmoc | tBu | DIPCDI/HOBt | 5eq-45분 |
Glu | Fmoc | OtBu | DIPCDI/HOBt | 5eq-45분 |
Leu | Fmoc | DIPCDI/HOBt | 5eq-45분 | |
Ala | Fmoc | DIPCDI/HOBt | 5eq-45분 | |
Arg | Fmoc | Pbf | DIPCDI/HOBt | 5eq-45분 |
Claims (24)
- 일반식 (I)에 해당하는, 선형이거나 또는 시스테인간 이황화 다리에 의해 고리화된 형태의 합성 펩티드.Δ-Z-TrpGlyCys-Θ-CysTyrThrSer-Ω (Ⅰ)[상기 일반식 (I)에서,- Δ는 비오티닐 라디칼, 비오시티닐 라디칼, 수소 원자, 아세틸(CH3CO-) 라디칼, 1개 또는 2개의 티올을 함유할 수 있는 지방족 사슬, 알데히드 작용기 및 아민 작용기로 이루어진 군으로부터 선택되며,- Z는 하기로 이루어진 군으로부터 선택되는 펩티드 서열이고:LeuLeuSerSerLeuLeuAsnSerArgLeuAsnSerAlaLeuGluThrLeuLeuGlnAsnGlnGlnLeuLeuAsnSerAlaLeuGluThrLeuLeuGlnAsnGlnGlnLeuLeuAspLeuAlaLeuGluThrLeuLeuGlnAsnGlnGlnLeuLeuAsnIleLeuAsnGlnGlnArgLeuLeuAsnSer, 및ArgAlaLeuGluThrLeuLeuAsnGlnGlnArgLeuLeuAsnSer;- Θ는 하기로 이루어진 군으로부터 선택되는 펩티트 서열이며:ArgGlyArgLeuIleArgGlyArgLeuValArgGlyLysLeuIleArgGlyLysLeuValLysGlyArgLeuIleLysGlyArgLeuVal- 세린의 -CO-기에 부착된 Ω는 하기로 이루어진 군으로부터 선택된다:히드록시기 및하기의 식을 갖는 펩티드 서열Val-ΨValArgTrpAsnGluThr-Ψ,ValGlnTrpAsnGluThr-Ψ, 및ValGlnTrpAsnSerThr-Ψ,(상기 식에서, 발린 또는 트레오닌의 -CO- 잔기에 부착된 Ψ는 OH기, NH2기, 1개 내지 6개의 탄소 원자를 함유하는 알콕시 라디칼로 이루어진 군으로부터 선택된다)
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제 1 항에 있어서,상기 Δ는 1개 내지 6개의 탄소 원자의 알킬 사슬, 2개 내지 6개의 탄소 원자의 알케닐 사슬, 및 2개 내지 6개의 탄소 원자의 아미노알킬카르보닐 사슬로 이루어진 군으로부터 선택되는 지방족 사슬인 것을 특징으로 하는 일반식 (I)의 합성 펩티드.
- 제 1 항에 있어서,다음 서열 중 어느 하나를 포함하는 것을 특징으로 하는 일반식 (Ⅰ)의 합성 펩티드.서열 번호 2LLSLWGCRGRLVCYTSVQWNET 또는LeuLeuSerLeuTrpGlyCysArgGlyArgLeuValCysTyrThrSerValGlnTrpAsnGluThr1 5 10 15 20 22서열 번호 3LLSSWGCKGRLVCYTSVQWNET 또는LeuLeuSerSerTrpGlyCysLysGlyArgLeuValCysTyrThrSerValGlnTrpAsnGluThr1 5 10 15 20 22서열 번호 4LLSSWGCKGRLVCYTSVQWNST 또는LeuLeuSerSerTrpGlyCysLysGlyArgLeuValCysTyrThrSerValGlnTrpAsnSerThr1 5 10 15 20 22서열 번호 5LLQSWGCKGRLVCYTSVQWNST 또는LeuLeuGlnSerTrpGlyCysLysGlyArgLeuValCysTyrThrSerValGlnTrpAsnSerThr1 5 10 15 20 22서열 번호 8LLSSWGCRGRLVCYTSVQWNET 또는LeuLeuSerSerTrpGlyCysArgGlyArgLeuValCysTyrThrSerValGlnTrpAsnGluThr1 5 10 15 20 22서열 번호 9LLSSWGCKGRLVCYTS 또는LeuLeuSerSerTrpGlyCysLysGlyArgLeuValCysTyrThrSer1 5 10 15서열 번호 10LLNSWGCKGRLVCYTS 또는LeuLeuAsnSerTrpGlyCysLysGlyArgLeuValCysTyrThrSer1 5 10 15서열 번호 11ALETLLQNQQLLNSWGCRGRLVCYTSVRWNET 또는AlaLeuGluThrLeuLeuGlnAsnGlnGlnLeuLeuAsnSerTrpGlyCysArgGly1 5 10 15ArgLeuValCysTyrThrSerValArgTrpAsnGluThr20 25 30서열 번호 12ALETLLQNQQLLNIWGCRGRLVCYTSVRWNET 또는AlaLeuGluThrLeuLeuGlnAsnGlnGlnLeuLeuAsnIleTrpGlyCysArgGly1 5 10 15ArgLeuValCysTyrThrSerValArgTrpAsnGluThr20 25 30서열 번호 13ALETLLQNQQLLDLWGCRGRLVCYTSVRWNET 또는AlaLeuGluThrLeuLeuGlnAsnGlnGlnLeuLeuAspLeuTrpGlyCysArgGly1 5 10 15ArgLeuValCysTyrThrSerValArgTrpAsnGluThr20 25 30서열 번호 14LNQQRLLNSWGCKGRLVCYTSV 또는LeuAsnGlnGlnArgLeuLeuAsnSerTrpGlyCysLysGlyArgLeuValCysTyrThrSerVal1 5 10 15 20서열 번호 15RALETLLNQQRLLNSWGCKGRLVCYTSV 또는ArgAlaLeuGluThrLeuLeuAsnGlnGlnArgLeuLeuAsnSerTrpGlyCysLys1 5 10 15GlyArgLeuValCysTyrThrSerVal20 25서열 번호 16RLNSWGCKGRLVCYTSV 또는ArgLeuAsnSerTrpGlyCysLysGlyArgLeuValCysTyrThrSerVal1 5 10 15
- 제 1 항의 일반식(I)의 하나 이상의 합성 펩티드를 함유하는 조성물로서, 상기 펩티드는 동결-건조되거나 또는 물로 희석되어 존재하는 것을 특징으로 하는 조성물.
- 제 17 항에 있어서,일반식 (I), 서열 번호 3, 및 서열 번호 1 중 하나 이상의 합성 펩티드를 함유하는 것을 특징으로 하는 조성물.
- 제 1 항의 일반식 (I)의 하나 이상의 합성 펩티드와 하나 이상의 그룹 O HIV-1 재조합 펩티드를 함유하는 것을 특징으로 하는 조성물.
- 제 1 항의 일반식 (I)의 하나 이상의 합성 펩티드와 하나 이상의 HIV-1, HIV-2, 또는 HIV-1 및 HIV-2 재조합 또는 합성 펩티드를 함유하는 것을 특징으로 하는 조성물.
- 그룹 O HIV-1 감염을 검출하는 면역분석 방법으로서,a) 항-그룹 O HIV-1 항체를 함유할 것으로 예상되는 환자로부터 시료를 취하는 단계;b) 검출가능하게 표시된 제 1 항의 일반식 (I)의 하나 이상의 합성 펩티드를 상기 시료와 접촉시키는 단계;c) 상기 펩티드와 상기 항체 사이의 복합체의 존재 여부를 검출하는 단계; 및d) 선택적으로 시료내의 상기 항체의 양을 분석하는 단계(여기서, 상기 펩티드와 상기 항체 사이의 복합체의 존재는 그룹 O HIV-1 감염을 나타냄)를 포함하는 것을 특징으로 하는 방법.
- 그룹 O HIV-1 감염을 검출하는 면역분석 방법으로서,a) 항-그룹 O HIV-1 항체를 함유할 것으로 예상되는 환자로부터 시료를 취하는 단계;b) 검출가능하게 표시된 제 17 항의 일반식 (I)의 하나 이상의 합성 펩티드를 상기 시료와 접촉시키는 단계;c) 상기 펩티드와 상기 항체 사이의 복합체의 존재 여부를 검출하는 단계; 및d) 선택적으로 시료내의 상기 항체의 양을 분석하는 단계(여기서, 상기 펩티드와 상기 항체 사이의 복합체의 존재는 그룹 O HIV-1 감염을 나타냄)를 포함하는 것을 특징으로 하는 방법.
- 그룹 O HIV-1 특이성 항체를 검출하는 진단 키트(diagnostic kit)로서,a) 제 1 항의 일반식 (I)의 하나 이상의 합성 펩티드를 포함하는 제1 용기(first container), 및b) 상기 항체와 상기 펩티드 사이의 복합체를 검출하는 적당한 수단을 포함하는 제2 용기(second container)를 포함하는 것을 특징으로 하는 진단 키트.
- 그룹 O HIV-1 특이성 항체를 검출하는 진단 키트로서,a) 제 17 항의 일반식 (I)의 하나 이상의 합성 펩티드를 포함하는 제1 용기, 및b) 상기 항체와 상기 펩티드 사이의 복합체를 검출하는 적당한 수단을 포함하는 제2 용기를 포함하는 것을 특징으로 하는 진단 키트.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR97/04356 | 1997-04-09 | ||
FR9704356A FR2761993B1 (fr) | 1997-04-09 | 1997-04-09 | Peptides synthetiques utilisables dans les essais biologiques pour la detection des infections dues aux virus vih 1 groupe 0 |
FR98/02212 | 1998-02-24 | ||
FR9802212A FR2775287B1 (fr) | 1998-02-24 | 1998-02-24 | Peptides synthetiques consensus utilisables dans les essais biologiques pour la detection des infections dues aux virus vih 1 du groupe o |
PCT/FR1998/000691 WO1998045323A1 (fr) | 1997-04-09 | 1998-04-06 | Peptides synthetiques utilisables dans les essais biologiques pour la detection des infections dues aux virus vih-1 du groupe o |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010006216A KR20010006216A (ko) | 2001-01-26 |
KR100451312B1 true KR100451312B1 (ko) | 2004-10-06 |
Family
ID=26233456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-1999-7009296A KR100451312B1 (ko) | 1997-04-09 | 1998-04-06 | 그룹 오 에이취아이브이-1 바이러스에 기인하는 감염의 검출을 위한 생물학적 시험에 사용가능한 합성 펩티드 |
Country Status (20)
Country | Link |
---|---|
US (2) | US7053175B1 (ko) |
EP (1) | EP0973802B1 (ko) |
JP (1) | JP3560987B2 (ko) |
KR (1) | KR100451312B1 (ko) |
CN (1) | CN1215082C (ko) |
AT (1) | ATE343590T1 (ko) |
AU (1) | AU740231B2 (ko) |
BR (1) | BRPI9809078B8 (ko) |
CA (1) | CA2286344C (ko) |
CZ (1) | CZ300927B6 (ko) |
DE (1) | DE69836265T2 (ko) |
ES (1) | ES2275305T3 (ko) |
IL (2) | IL132166A0 (ko) |
NO (1) | NO329149B1 (ko) |
NZ (1) | NZ500015A (ko) |
PL (1) | PL194863B1 (ko) |
PT (1) | PT973802E (ko) |
RU (1) | RU2184742C2 (ko) |
TR (1) | TR199902757T2 (ko) |
WO (1) | WO1998045323A1 (ko) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69836265T2 (de) * | 1997-04-09 | 2007-05-31 | Bio-Rad Pasteur | Synthetische peptide für testverfahren zur bestimmung der infektion mit virus hiv1 der gruppe o |
CA2676762C (en) * | 1998-11-30 | 2015-12-29 | Ortho-Clinical Diagnostics, Inc. | Peptides for the detection of hiv-1 group o |
FR2874017B1 (fr) * | 2004-08-06 | 2006-11-24 | Bio Rad Pasteur Sa | Peptides vih-1 modifies et leur utilisation en detection d'anticorps anti-vih |
US9658220B2 (en) | 2012-06-22 | 2017-05-23 | Bio-Rad Laboratories, Inc. | Human factor XIII as a normalization control for immunoassays |
CN112481246B (zh) * | 2020-12-16 | 2022-03-29 | 熊猫乳品集团股份有限公司 | 一种生物活性多肽fspankkltpkky及其制备方法和应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204259A (en) | 1988-05-06 | 1993-04-20 | Pharmacia Genetic Engineering, Inc. | Methods and systems for producing HIV antigens |
AU677225B2 (en) | 1992-10-06 | 1997-04-17 | Dade Behring Marburg Gmbh | Retrovirus from the HIV group and its use |
DE4405810A1 (de) | 1994-02-23 | 1995-08-24 | Behringwerke Ag | Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung |
GB9410044D0 (en) | 1994-05-19 | 1994-07-06 | Int Murex Tech Corp | Assay |
DE4430972A1 (de) | 1994-07-25 | 1996-02-01 | Boehringer Mannheim Gmbh | Bestimmung von spezifischem Immunglobulin unter Verwendung multipler Antigene |
DE69535601T3 (de) * | 1994-10-20 | 2012-04-05 | Institut Pasteur | Nukleotiden-sequenzen aus retroviren-antigenen hiv-i gruppe (oder untergruppe) o |
DE19505262C2 (de) | 1995-02-16 | 1998-06-18 | Behring Diagnostics Gmbh | Retrovirus aus der HIV-Gruppe und dessen Verwendung |
FR2731013B1 (fr) * | 1995-02-27 | 1997-05-16 | Inst Nat Sante Rech Med | Vih-1 de groupe o, fragments desdits virus, ainsi que leurs applications |
AU5100696A (en) | 1995-03-02 | 1996-09-18 | Akzo Nobel N.V. | Specific hiv-1 group o antigens |
US5569553A (en) | 1995-03-08 | 1996-10-29 | Wilson Greatbatch Ltd. | Battery design for achieving end-of-life indication during electrical discharge |
DE19622088A1 (de) | 1996-05-31 | 1997-12-04 | Boehringer Mannheim Gmbh | Anti-HIV-Antikörper als Kontrollproben |
DE69836265T2 (de) * | 1997-04-09 | 2007-05-31 | Bio-Rad Pasteur | Synthetische peptide für testverfahren zur bestimmung der infektion mit virus hiv1 der gruppe o |
CA2296442A1 (en) | 1997-07-18 | 1999-01-28 | Innogenetics N.V. | Hiv-1 group o antigens and uses thereof |
-
1998
- 1998-04-06 DE DE69836265T patent/DE69836265T2/de not_active Expired - Lifetime
- 1998-04-06 IL IL13216698A patent/IL132166A0/xx active IP Right Grant
- 1998-04-06 CN CNB988052024A patent/CN1215082C/zh not_active Expired - Lifetime
- 1998-04-06 KR KR10-1999-7009296A patent/KR100451312B1/ko not_active IP Right Cessation
- 1998-04-06 ES ES98920571T patent/ES2275305T3/es not_active Expired - Lifetime
- 1998-04-06 WO PCT/FR1998/000691 patent/WO1998045323A1/fr active IP Right Grant
- 1998-04-06 RU RU99123443/04A patent/RU2184742C2/ru active
- 1998-04-06 BR BRPI9809078A patent/BRPI9809078B8/pt not_active IP Right Cessation
- 1998-04-06 TR TR1999/02757T patent/TR199902757T2/xx unknown
- 1998-04-06 AT AT98920571T patent/ATE343590T1/de not_active IP Right Cessation
- 1998-04-06 EP EP98920571A patent/EP0973802B1/fr not_active Expired - Lifetime
- 1998-04-06 US US09/147,362 patent/US7053175B1/en not_active Expired - Lifetime
- 1998-04-06 AU AU73386/98A patent/AU740231B2/en not_active Expired
- 1998-04-06 CZ CZ0357599A patent/CZ300927B6/cs unknown
- 1998-04-06 CA CA2286344A patent/CA2286344C/fr not_active Expired - Lifetime
- 1998-04-06 PT PT98920571T patent/PT973802E/pt unknown
- 1998-04-06 JP JP54245598A patent/JP3560987B2/ja not_active Expired - Lifetime
- 1998-04-06 PL PL336115A patent/PL194863B1/pl unknown
- 1998-04-06 NZ NZ500015A patent/NZ500015A/en not_active IP Right Cessation
-
1999
- 1999-09-30 IL IL132166A patent/IL132166A/en not_active IP Right Cessation
- 1999-10-08 NO NO19994929A patent/NO329149B1/no not_active IP Right Cessation
-
2006
- 2006-04-13 US US11/402,876 patent/US7838001B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2851278B2 (ja) | Htlv−iに対する抗体の検出のための抗原,atlのためのワクチンとしてのペプチド組成物およびそれを用いる方法 | |
JP3020289B2 (ja) | Hivウイルス類のエンベロープ糖タンパク質由来のペプチド、これらのウイルスによって起こる感染の検出とエイズ症に対する予防接種へのこれらペプチドの用途 | |
US7838001B2 (en) | Synthetic peptides useful in biological essays for detecting infections caused by group O HIV-1 viruses | |
Kuroda et al. | Detection of antibodies to human T‐lymphotropic virus type I by using synthetic peptides | |
JP2650217B2 (ja) | Htlv―1感染の診断、治療及び予防接種のためのペプチド | |
JP2643598B2 (ja) | Htlv‐▲i▼抗体に対する免疫反応性を有する合成ペプチド組成物 | |
EP0326490B1 (en) | Synthetic peptides and mixtures thereof for detecting HIV antibodies | |
EP0439077B1 (en) | Synthetic peptide compositions with immunoreactivities to antibodies to HTLV | |
US5476765A (en) | Synthetic peptide compositions with immunoreactivities to antibodies to HTLV and as vaccines | |
Sibille et al. | Comparison of serological tests for the diagnosis of feline immunodeficiency virus infection of cats | |
EP1000177B1 (en) | Synthetic antigens for the detection of antibodies having immunoreactivity against hiv virus | |
US5283320A (en) | Peptides for HTLV-2 infection diagnosis of, therapy for, vaccination against, for distinguishing between HTLV-1 and HTLV-2 infections and antibodies derived therefrom | |
CN109836478A (zh) | 非洲猪瘟病毒p11.5蛋白特异性多克隆抗体的制备方法及应用 | |
MXPA99009106A (en) | Synthetic peptides useful in biological assays for detecting infections caused by group o hiv-1 viruses | |
US5681696A (en) | Synthetic peptide compositions with immunoreactivities to antibodies to HTLV | |
US6218102B1 (en) | Synthetic peptides and mixtures thereof for detecting HIV antibodies | |
JPH05230097A (ja) | B型肝炎ウイルスのHBc抗原由来の合成ペプチド、このウイルスによる感染を検出すること及び抗B型肝炎ワクチンのための該ペプチドの使用 | |
US20010014470A1 (en) | T-lymphotrophic virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120822 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20130827 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20140825 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20150908 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20160908 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20170911 Year of fee payment: 14 |
|
EXPY | Expiration of term |